In Vitro Cell Viability Effects of Doxorubicin Analogs in Uterine Soft Tissue Sarcomas

Document Type

Student Presentation

Presentation Date

April 2017

Faculty Sponsor

Ken Cornell


Doxorubicin (DOX) is a topoisomerase inhibitor used as a primary chemotherapeutic agent on soft tissue sarcomas (STS). However, the 30% overall response rate to DOX has not improved in over 50 years. DOX is highly toxic with side effects that include drug-related cardiotoxicity, irreversible congestive heart failure. To improve drug efficacy and reduce side effects, the DOX analogs MGPX-150, PMGPX-150, and CMGPX-150, were synthesized and their inhibitory concentration at half maxima (IC50) values were studied. These values were obtained through the Alamar Blue Assay protocol, and were tested against the Human Uterine Sarcoma (MES-SA) cell line. Based on the IC50 values, PM-GPX150 and CM-GPX150 were strong inhibitors of cell growth, whereas M-GPX150 was ten-fold more potent against the MES-SA cell line.

This document is currently not available here.